SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Wednesday reported a loss of $19.2 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 22 cents.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.
The biopharmaceutical company posted revenue of $53.9 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $229.2 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KURA at https://www.zacks.com/ap/KURA
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.